This is a routine, pre-planned insider sale under a 10b5-1 plan by a director. The small dollar amount and plan adoption date over a year ago indicate no material non-public information concern. No action warranted.
QURE drugs
QURE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $29.88entry
- T+1 · 6mo ago −6.33%α −6.72% · $27.99
- T+5 · 5mo ago −10.24%α −6.42% · $26.82
- T+20 · 5mo ago +39.93%α +40.93% · $41.81
- T+60 · 3mo ago +65.86%α +63.36% · $49.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Jack Kaye filed a Form 144 notice of intent to sell 2,645 ordinary shares of uniQure N.V., valued at approximately $79,384, on June 3, 2026. The sale is pursuant to a Rule 10b5-1 trading plan and follows a stock option exercise. The small size relative to the company's $1.7B market cap makes this a routine insider transaction with minimal market impact.
Key Facts
- Director Jack Kaye filed Form 144 to sell 2,645 ordinary shares.
- Estimated aggregate value of the proposed sale is $79,384.
- Sale is executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
- Transaction follows a stock option exercise and is for cash.
- The sale represents approximately 0.0004% of the company's $1.7B market cap.
Financial Impact
Proposed sale of 2,645 shares valued at $79,384, representing a negligible fraction of market cap.
Risk Factors
- Insider selling pattern could escalate if additional directors or officers file similar notices.
- Form 144 is only an intent to sell; the actual sale may not occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001973379-26-000219 |
| Document: 0001973379-26-000219-index.html | 0001973379-26-000219 |
| Document: 0001973379-26-000219.txt | 0001973379-26-000219 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers